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Abstract
Background
The aim of this study is to present average annual healthcare costs for Dutch renal replace-
ment therapy (RRT) patients for 7 treatment modalities.
Methods
Health insurance claims data from 2012–2014 were used. All patients with a 2014 claim for
dialysis or kidney transplantation were selected. The RRT related and RRT unrelated aver-
age annual healthcare costs were analysed for 5 dialysis modalities (in-centre haemodialy-
sis (CHD), home haemodialysis (HHD), continuous ambulatory peritoneal dialysis (CAPD),
automated peritoneal dialysis (APD) and multiple dialysis modalities in a year (Mix group))
and 2 transplant modalities (kidney from living and deceased donor, respectively).
Results
The total average annual healthcare costs in 2014 ranged from €77,566 (SD = €27,237) for
CAPD patients to €105,833 (SD = €30,239) for patients in the Mix group. For all dialysis
modalities, the vast majority (72–84%) of costs was RRT related. Patients on haemodialysis
�4x/week had significantly higher average annual costs compared to those dialyzing 3x/
week (Δ€19,122). Costs for kidney transplant recipients were €85,127 (SD = €39,679) in the
year of transplantation and rapidly declined in the first and second year after successful
transplantation (resp. €29,612 (SD = €34,099) and €15,018 (SD = €16,186)). Transplanta-
tion with a deceased donor kidney resulted in higher costs (€99,450, SD = €36,036)) in the
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year of transplantation compared to a living donor kidney transplantation (€73,376, SD =
€38,666).
Conclusions
CAPD patients have the lowest costs compared to other dialysis modalities. Costs in the
year of transplantation are 25% lower for patients with kidneys from living vs. deceased
donor. After successful transplantation, annual costs decline substantially to a level that is
approximately 14–19% of annual dialysis costs.
Introduction
End-stage renal disease (ESRD) is ranked among the top 20 leading causes of decrease in qual-
ity of life and loss of life years, and has one of the highest disease burdens worldwide [1, 2]. In
the Netherlands on January 1st 2015, 16,277 people were dependent on renal replacement ther-
apy (RRT) with an annual incidence of approximately 2,000 patients [3]. Although in the
Netherlands the incidence rate of RRT has stabilized, the number of prevalent patients contin-
ues to rise due to a relatively high number of renal transplantations [4]. This implies that the
economic burden of RRT treatment increases as well. Healthcare systems face a major chal-
lenge as a considerable amount of the often limited healthcare budget is spent on RRT [5].
According to the National Institute of Public Health and the Environment (RIVM), the total
healthcare cost for chronic renal failure was 800 million Euros in 2011 [2]. As the vast majority
of these costs is related to RRT, this implies that 1% of the national healthcare budget of the
Netherlands was spent on 0,1% of the population [6].
RRT has always served as a classical example of lifesaving treatment with very high per per-
son costs and this essentially has not changed over the past decennia. However, comprehensive
cost estimates of RRT in the Netherlands are based on a study from the 1990’s[6]. More recent
studies only incorporated one or a few RRT modalities [7, 8]. Also, recent developments, such
as living-donor related kidney transplantation and high-frequency dialysis, necessitate a com-
prehensive costing study that includes such new therapeutic possibilities.
Several European studies have recently used health insurance claims to investigate national
healthcare expenditures related to RRT [9–12]. Dutch health insurance claims contain details
on expenditures and treatment of different RRT modality and enable to perform a comprehen-
sive study on healthcare expenditure of patients on different RRT modalities with a nationwide
coverage.
The aim of this study is to provide detailed estimates of the average annual costs per patient
for seven RRT modalities. Besides distinguishing between dialysis therapies, we also include
transplantation costs by source of kidney donor, living or deceased, and haemodialysis (HD)
costs by frequency of dialysis.
Materials and methods
Data source
In the Netherlands healthcare insurance is obligatory; almost all citizens have a healthcare
insurance [13]. Vektis collects and manages claims data of all Dutch health insurance compa-
nies. These claims are related to all healthcare procedures covered by the Health Insurance
Act, including the costs of compulsory co-payments [14]. The Vektis database covers 99% of
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insured people living in the Netherlands and contains demographic information, including
sex, year of birth and date of death. To ensure privacy, Vektis pseudonymised the persons’
national identification number and allowed data access only in a secured environment. All
authors only had access to de-identified data. For the use of this national data, permission of
all contributing insurance companies was provided (S1 File).
Study population
From all adults (�19 years) in the Vektis claims database who had at least one health insurance
claim related to RRT we included those patients on chronic RRT and excluded those with inci-
dental use (e.g. acute dialysis) or unjustified (erroneous) claims. Dialysis patients were selected
using health claims in the year 2014 and kidney transplant patients were identified using claims
in the period January 1, 2012 to December 31, 2014. We differentiated 7 RRT modalities: (1) in-
centre haemodialysis (CHD), (2) home haemodialysis (HHD), (3) continuous ambulatory peri-
toneal dialysis (CAPD), (4) automated peritoneal dialysis (APD), (5) multiple dialysis modalities
within a year (Mix), (6) living kidney donor transplant recipients and (7) deceased kidney
donor transplant recipients (Fig 1A and 1B, see also S2 File). After classification, we validated
Fig 1. Classification of RRT modalities. Note: Fig 1A: Classification of dialysis patients; CHD = Centre Haemodialysis; HHD = Home Haemodialysis;
APD = Automated Peritoneal Dialysis; CAPD = Continuous Ambulatory Peritoneal Dialysis; Mix Group = dialysis modality changed in 2014; FYD = full year on
dialysis; Fig 1B: Classification of transplantation patients. We included only the first received kidney transplantation in the study period of 2012–2014. � Excluded
patients are not represented in the figure.
https://doi.org/10.1371/journal.pone.0220800.g001
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the number of patients per modality in an external database, the Dutch Renal Registry (Renine),
that serves as gold standard because of its complete coverage of chronic RRT. Correspondence
between the two databases was high (93.8–99.1%, see S3 File).
Cost variables
We estimated healthcare costs by using registered health claims (reimbursement data). Costs
were distinguished according to different healthcare components. First, costs directly related
to RRT, based on diagnosis-related group codes (DRG’s), were identified and included all
costs of the dialysis procedure (including access surgery and hospitalization for access sur-
gery), the kidney transplant (including donor expenses) as well as the pre- and post-transplant
care. More specifically, RRT related costs include all medications used during dialysis (e.g.
EPO, phosphate binders), staff costs, including physician fees, laboratory assessments and
other diagnostics as included in RRT clinical guidelines (e.g. chest X-ray). Also, equipment
and devices needed, e.g. dialysis machines for home dialysis, is included here. Finally, overhead
costs, e.g. for water and energy are included. Second, non-RRT costs were defined as all
remaining in- and outpatient DRG costs not directly related to RRT, such as primary care,
mental healthcare, medication, medical devices, transportation, healthcare costs incurred
abroad and other healthcare costs. These non-RRT costs may incur dialysis related costs as
well, e.g. transportation costs to and from the dialysis center, but these costs cannot be attrib-
uted with 100% certainty to RRT.
Cost data are provided as annual costs, averaged over all patients in a specific modality
group. To provide meaningful cost estimates for patients that are not a full year on RRT, e.g.
incident and deceased patients, we calculated average 4-week healthcare costs for these patient
subgroups.
Statistical analysis
Descriptive statistics (age, gender and co-morbidity) are presented per treatment modality.
The presence of comorbidities was based on medication (see S4 File). Healthcare costs are pre-
sented as mean with standard deviation. The average annual costs of haemodialysis patients
were calculated depending on weekly dialysis frequency. To test for statistical significance of
differences in healthcare expenditure between groups (lower and higher frequency of haemo-
dialysis; donor source), we applied the non-parametric Wilcoxon-Mann-Whitney test, as cost
data were non-normally distributed. Finally, healthcare costs were calculated per treatment
state. To accommodate for differences in total treatment time between incident, full year on
dialysis (FYD) and deceased patients, we calculated the cost of 4 weeks of treatment (4-week
costs) per treatment state, as the sum of yearly costs divided by total treatment time (TTT) in
days � 28 days. All costs are reported in euros (1 euro = 1.11454 US dollar–exchange rate of
31th of July 2019) and converted to the year 2014 according to the Dutch Consumer Price
Index (2012 to 2014: 1.035; 2013 to 2014: 1.010) [15]. All analyses were conducted using SAS,
version 9.4 (SAS Institute Inc., Cary, NC).
Results
Patient characteristics by RRT modality
Overall, 7,827 persons could reliably be attributed to one of seven RRT modalities in 2014
(Table 1). Of these, 6,876 were dialysis patients and 951 patients received a kidney transplant.
On average, HHD patients and transplant recipients were younger and had fewer comorbidi-
ties than patients on other modalities, whereas more males than females received RRT.
Healthcare costs of patients on different renal replacement modalities
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Annual healthcare costs per dialysis modality
Table 2 shows average annual healthcare costs in 2014 of FYD patients by modality. RRT costs
ranged from €61,025 for CAPD patients to €76,531 for Mix group patients. The vast majority
Table 1. Patient characteristics per RRT modality (>75% TTTa) in the year 2014.
Dialysis patients Kidney transplant recipients
On Haemodialysis (HD) On Peritoneal dialysis
(PD)
Mix between dialysis treatments a Performed Transplants c
CHD b HHD b APD b CAPD b Mix Group b Deceased donor Living donor
N (%) 5594 (81%)d 187 (3%) 431 (6%) 411 (6%) 253 (4%) 441 (46%) e 510 (54%)
Age (mean, SD) 69.6 (13.9) 58.3 (13.5) 65.7 (14.3) 69.0 (13.1) 63.3 (14.9) 57.0 (12.6) 50.7 (13.7)
Gender (% men) 59% 65% 62% 61% 66% 63% 60%
Nr. of comorbidities (mean, SD) 1.0 (0.9) 0.7 (0.8) 1.1 (0.9) 1.2 (0.9) 1.0 (0.9) 1.0 (0.8) 0.7 (0.8)
a TTT = Total Treatment Time in year 2014 applies to dialysis patients only. RRT modality groups are exclusive, implying that patients are only part of one ‘stable’ RRT
modality.
b CHD = Centre Haemodialysis; HHD = Home Haemodialysis; APD = Automated Peritoneal Dialysis; CAPD = Continuous Ambulatory Peritoneal Dialysis; Mix
Group = dialysis modality changed in 2014.
c We included only patients with a first kidney transplantation in 2014 in the study period of 2012–2014.
d Reading example: 81% of the dialysis patients were categorized as CHD patients.
e Reading example: 46% of the kidney transplant recipents received a decased donor kidney.
https://doi.org/10.1371/journal.pone.0220800.t001
Table 2. Average annual healthcare costs per dialysis modality, for FYD patients (Full Year on Dialysis) (€ 2014).
Haemodialysis (HD) Peritoneal dialysis (PD)
CHD a (n = 3,430) HHD a (n = 174) CAPD a (n = 198) APD a (n = 282) Mix Group a (n = 125)
Mean (Std Dev) %
users
Mean (Std Dev) %
users
Mean (Std Dev) %
users
Mean (Std Dev) %
users
Mean (Std Dev) %
users
Dialysis modality €
69,887
(7,274) 100% €
71,409
(5,645) 100% €
60,084
(3,693) 100% €
73,437
(3,620) 100% € 73,055 (10,002) 100%
Dialysis access € 1,645 (2,885) 42% € 1,187 (2,420) 36% € 529 (1,530) 15% € 385 (1,475) 12% € 3,137 (3,568) 64%
Pre-transplant
procedures
€ 201 (1,379) 11% € 239 (791) 19% € 413 (1,805) 20% € 392 (1,468) 20% € 339 (1,186) 22%
Total RRT costs €
71,734
(8,106) 100% €
72,834
(6,338) 100% €
61,025
(4,644) 100% €
74,215
(4,152) 100% € 76,531 (10,747) 100%
Hospital (no RRT) € 8,563 (13,813) 93% € 5,785 (7,775) 93% € 9,115 (22,633) 90% € 7,611 (13,401) 91% € 16,286 (21,181) 99%
Primary care € 395 (606) 98% € 340 (520) 97% € 351 (437) 97% € 346 (508) 99% € 446 (756) 98%
Mental health care € 236 (2,630) 5% € 13 (78) 3% € 164 (1,617) 3% € 87 (601) 4% € 414 (3,239) 9%
Medication b € 4,325 (3,395) 98% € 4,277 (4,081) 99% € 3,939 (3,383) 98% € 4,382 (6,199) 99% € 4,690 (6,392) 99%
Medical devices € 911 (1,787) 70% € 2,808 (2,068) 90% € 1,726 (1,535) 95% € 1,991 (1,515) 95% € 2,684 (2,955) 96%
Health care abroad € 171 (846) 9% € 355 (917) 21% € 1 (17) 2% € 202 (2,266) 2% € 12 (96) 2%
Transportation € 5,455 (5,499) 96% € 570 (973) 49% € 504 (1,015) 41% € 461 (964) 34% € 2,856 (2,633) 87%
Other € 827 (4,007) 20% € 69 (489) 13% € 739 (3,785) 12% € 639 (3,668) 13% € 1,914 (5,756) 27%
Total average
annual costs
€
92,616
(21,500) 100% €
87,051
(12,648) 100% €
77,566
(27,237) 100% €
89,932
(18,890) 100% €
105,833
(30,239) 100%
a CHD = Centre Haemodialysis; HHD = Home Haemodialysis; APD = Automated Peritoneal Dialysis; CAPD = Continuous Ambulatory Peritoneal Dialysis; Mix
Group = dialysis modality changed in 2014.
b Medication is all medication distributed by pharmacy outside the hospital. Other types of costs, i.e. dialysis modality and hospitalization may also include medication
costs. In the Netherlands, inpatient medication is part of the DRG and can therefore not be detected as a separate expenditure in claims data.
https://doi.org/10.1371/journal.pone.0220800.t002
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of costs was related to the dialysis itself, with relatively small amounts for pre-transplant proce-
dures and dialysis access, but not in the Mix group. This group experiences by definition a
change between modalities necessitating costs for access procedures. Three non-RRT health-
care components stand out with relatively high amounts, i.e. hospital costs, medication and
transportation costs. Hospital costs unrelated to RRT for patients in the Mix group (€16,286)
were much higher than in other groups. The third most expensive cost item was medication
(outside the hospital) with the lowest costs for CAPD (€3,939) and, again, highest costs for the
Mix group (€4,690). Transportation costs (taxi costs) were highest in CHD patients (€5,455),
while home dialysis patients (HHD and (C)APD) had almost ten-fold lower expenditure, obvi-
ously related to the less frequent hospital visits of these groups. RRT related costs of HHD
were in the same order of magnitude as costs of CHD, this is related to the possibility to use
individual nursing assistance at home for HHD patients.
Annual health care costs by dialysis frequency
A reliable dialysis frequency pattern could be established for 3412 out of 3604 FYD haemodia-
lysis patients (Fig 1). Only 8% of these patients dialyzed�4 times/week. Of these, the vast
majority dialyzed 4 or 5 times/week while 19 patients (7%) received�6 sessions/week.
Table 3 shows that frequent users had higher average costs related to RRT (€88,200) in
comparison with less frequent users (€69,744). Hospital costs unrelated to RRT did not differ
between these groups. Primary care, medical devices, healthcare abroad and transportation
costs did however differ between the two groups (although with small differences in euros).
Overall, cost differences between the high- and normal-intensity haemodialysis patients
amounted to €19,122, in favor of those who dialyze�3 times/week.
4-week healthcare costs per treatment state and dialysis modality
Fig 2 shows the 2014 average 4-week healthcare costs of 3 dialysis subgroups (indicated as
“treatment states”): (1) FYD patients, (2) incident patients and (3) deceased patients. Hence,
independent of the TTT or period alive, Fig 2 enables a comparison of the five dialysis modali-
ties per treatment state while including all healthcare spending over the year 2014. Incident
Table 3. Total average annual costs (€) depending on frequency of haemodialysis, for FYD patients (Full Year on Dialysis) only.
� 3 times per week (n = 3,142) �4 times per week (n = 270)
Mean (Std Dev) % users Mean (Std Dev) % users
N 3142 270
Total RRT costs� € 69,744 (5,067) 100% € 88,200 (10,985) 100%
Hospital costs not related to RRT € 8,301 (13,425) 92% € 8,818 (13,968) 95%
Primary care� € 396 (607) 98% € 335 (564) 99%
Mental health care € 244 (2,736) 5% € 47 (469) 4%
Medicationa € 4,292 (3,410) 98% € 4,349 (3,483) 99%
Medical devices� € 907 (1,734) 70% € 1,714 (2,274) 77%
Health care abroad� € 169 (831) 9% € 213 (727) 13%
Transportion� € 5,219 (5,276) 96% € 5,186 (7,516) 77%
Other € 848 (4,074) 20% € 379 (2,803) 17%
Total average annual costs� € 90,119 (19,981) € 109,241 (23,295)
�Significance at p<0.05 two-sided.
a Medication is all medication distributed by pharmacy outside the hospital. Other types of costs, i.e. dialysis modality and hospitalization may also include medication
costs. In the Netherlands, inpatient medication is part of the DRG and can therefore not be detected as a separate expenditure in claims data.
https://doi.org/10.1371/journal.pone.0220800.t003
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and deceased HHD patient numbers were too low in number to allow meaningful analysis. Fig
2 confirms that most costs of FYD are related to RRT. The highest 4-week expenditures
(€15,560) were made for patients starting CHD. For all dialysis modalities, incident and
deceased patients had high non-RRT related costs, while FYD patients had low non-RRT
related costs. Highest 4-week costs are associated with patients starting CHD and lowest
4-week costs were registered for stable CAPD patients.
Annual health care costs of kidney transplantation
Table 4 shows that the average annual healthcare costs in the year of transplantation are high
(€85,127) and comparable to annual healthcare costs of dialysis patients (€77.566 - €105.833,
see Table 2). The annual healthcare costs decline with time after surgery, with total annual
healthcare costs of €29,612 in the first and €15,018 in the second year after successful
transplantation.
At the beginning of the second year after transplantation, 911 out of 968 patients trans-
planted in 2012 were alive, however, 105 of these patients had experienced graft failure, as
appeared from claims indicating another kidney transplantation or a return to dialysis. Of the
patients with functioning graft (Table 4, last column, n = 806), average annual healthcare
expenditure was €5,139 lower than the average second year costs of all patients alive, irrespec-
tive of graft functioning.
Annual healthcare costs of patients according to donor source
Over a 3-year period (2012–2014) 1,554 patients received a kidney transplant from a living
kidney donor and 1,275 patients obtained a kidney from a deceased person (Table 5). RRT
related costs were most prominent in both groups, varying from 72% of all healthcare costs
(living donor) to 75% of costs (deceased donor). Absolute RRT related costs were almost
€22,000 higher in deceased donor kidney recipients. This was mostly due to higher dialysis
and transplant surgery related costs in recipients of a deceased donor kidney. On average, a
transplant from a deceased donor resulted in higher costs in all healthcare components, except
donor expenses, compared to receiving a transplant from a living donor. As a result, the total
Fig 2. 4-week average mean healthcare costs related to treatment states, per modality. Note: FYD = full year on dialysis; Incident = incident patients starting
treatment in 2014; Deceased = patients who died in 2014; CHD = Centre Haemodialysis; HHD = Home Haemodialysis; APD = Automated Peritoneal Dialysis;
CAPD = Continuous Ambulatory Peritoneal Dialysis; Mix Group = dialysis modality changed in 2014.
https://doi.org/10.1371/journal.pone.0220800.g002
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costs related to a deceased donor kidney transplant were substantially higher (€99,450 per
year) compared to those of a transplant with a living donor kidney (€73,376).
Discussion
Our study using health insurance claims showed high expenses for all dialysis modalities, with
annual expenditure ranging between €77,566 for CAPD to €92,616 for CHD and €105,833 for
patients of the Mix group. The vast majority of total health care expenses was related to RRT.
Patients who dialyzed more frequently had higher overall expenditure because higher RRT
related costs were not compensated by lower non-RRT related costs. In the year of kidney
transplantation, patients had expenses similar to those on dialysis, but expenses declined
steadily in the years post-transplant to €15,018 in the second year for those with a surviving
graft after transplantation. Our study found substantial higher expenditure for those who
received a kidney from a deceased donor compared to a living donor.
The fact that dialysis treatment is expensive confirms findings of both older [6] and more
recent [7–12] studies. Our study also confirms that expenses for CAPD are the lowest among
the dialysis modalities [16, 17]. Our study does not confirm observations from small cohort
studies showing that haemodialysis patients who dialyze more frequently have lower overall
costs [18–20]. The higher RRT related costs of patients who dialyze�4 times/week appeared
not to be compensated by lower expenses for other healthcare use. Here, we cannot exclude
the possibility that selection bias plays a role, with patients in more serve condition qualifying
for more intensive dialysis, leaving open the option that their costs would have been higher
should they have received regular dialysis 3 times per week. As our study only concerns costs,
Table 4. Total average annual healthcare costs per phase of transplantation.
Year of transplantation First yeara after
transplantation
Second year after
transplantation
Second year after successful
transplantation
N 2,829 1,825 911 806
Mean (Std Dev) % users Mean (Std Dev) % users Mean (Std Dev) % users Mean (Std Dev) % users
Preparatory research € 1,954 (7,911) 45% € 100 (857) 5% € 29 (223) 4% € 19 (205) 2%
Transplant operation € 22,748 (11,267) 100% € 1,150 (4,454) 9% € 242 (2,374) 2% € 55 (731) 1%
Guidanceb € 474 (1,154) 17% € 106 (474) 7% € 99 (394) 8% € 108 (413) 9%
After care € 6,803 (9,641) 74% € 4,396 (6,438) 85% € 1,831 (2,777) 82% € 1,817 (2,566) 86%
Donor expenses € 2,608 (5,466) 23% € 246 (1,623) 5% € 6 (102) 1% € 5 (84) 1%
Dialysis procedure (incl. access) € 28,020 (26,007) 74% € 5,048 (15,442) 21% € 3,635 (14,738) 10% € 0 (0) 0%
RRT related costs € 62,607 (31,064) 100% € 11,046 (18,815) 92% € 5,842 (15,612) 90% € 2,004 (2,647) 90%
Hospital (no RRT) € 9,550 (17,670) 97% € 7,242 (23,245) 87% € 5,698 (16,520) 86% € 4,694 (12,782) 86%
Primary care € 246 (328) 99% € 276 (377) 100% € 285 (506) 100% € 281 (522) 100%
Mental health care € 147 (1,597) 6% € 263 (3,392) 6% € 195 (1,306) 6% € 204 (1,380) 6%
Medicationc € 9,227 (6,458) 100% € 8,776 (5,422) 100% € 6,536 (4,253) 100% € 6,587 (4,258) 100%
Medical devices € 678 (1,395) 62% € 616 (1,375) 51% € 664 (1,640) 49% € 648 (1,671) 47%
Health care abroad € 215 (1,243) 10% € 59 (710) 4% € 74 (1,128) 5% € 52 (1,143) 4%
Transportation € 2,237 (3,504) 70% € 1,041 (2,307) 47% € 608 (1,999) 26% € 343 (1,099) 21%
Other € 220 (1,808) 13% € 293 (2,471) 12% € 256 (2,969) 10% € 180 (2,641) 11%
Total average annual costs € 85,127 (39,679) 100% € 29,612 (34,099) 100% € 20,156 (26,571) 100% € 15,018 (16,186) 100%
a A ‘year’ refers to a calendar year. For example, when the transplantation has taken place in 2014, the first year after transplantation was 2015
b Guidance are costs for the process before the transplantation
c Medication is all medication distributed by pharmacy outside the hospital. Other types of costs, i.e. dialysis modality and hospitalization may also include medication
costs. In the Netherlands, inpatient medication is part of the DRG and can therefore not be detected as a separate expenditure in claims data.
https://doi.org/10.1371/journal.pone.0220800.t004
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and not health outcomes (more intensive dialysis is reflected in better patient outcomes, such
as mortality and physical health [21]), a separate cost-effectiveness analysis comparing more
and less intensive dialysis treatment would be needed to find out whether additional costs are
balanced by better outcomes. Such a cost-effectiveness analysis should be undertaken from a
societal perspective, to include types of costs that we currently could not address, such as out-
of-pocket costs of patients and productivity costs related to the patients’ ability to maintain
employment.
Expenses for patients of the Mixed group were remarkably higher in many categories of
healthcare use, such as access procedures and medication. In particular, non-RRT related hos-
pital care expenditure in this group was higher than in patients stable on one dialysis modality.
This suggests that the switch between dialysis modalities may not only be rooted in therapy
failure itself, but also in the occurrence of other diseases that prevent continuation of the initial
modality and that are associated with higher non-RRT costs in itself. Indeed, a study from the
US [22] showed infections and cardiovascular diseases, mainly fluid overload, to be the most
important causes of a switch from peritoneal dialysis to haemodialyis. Also, patient character-
istics such as higher BMI and having diabetes were found to be associated with a switch
between dialysis modalities. We only had access to few background characteristics of patients,
such as age, sex and the number of comorbidities. Patients switching between modalities were
somewhat younger than most other dialysis groups, except HHD, but had similar number of
comorbidities. Patient groups may have also differed with regard to other, non-measured, pre-
dictors of switching between modalities.
Our study shows a clear cost advantage of transplantation using living donor kidneys com-
pared to deceased donor kidneys, despite additional health expenses for the donor. There was
a large difference in dialysis costs, i.e. the dialysis costs were higher for the group who received
Table 5. Total average annual costs of transplantation (year 0) by source of kidney donor (€).
Deceased donor Living donor Cost
Mean (Std Dev) % users Mean (Std Dev) % users difference
N 1275 1554
Preparatory research € 578 (2,254) 29% € 3,083 (10,343) 58% € 2,505 �
Transplant operation € 27,034 (12,083) 100% € 19,232 (9,162) 100% -€ 7,802 �
Guidance € 256 (847) 11% € 652 (1,329) 22% € 396 �
After care € 7,485 (11,034) 73% € 6,244 (8,287) 75% -€ 1,241
Donor expenses € 28 (254) 2% € 4,725 (6,663) 40% € 4,697 �
Dialysis procedure (incl. access) € 39,223 (24,281) 94% € 18,828 (23,674) 57% -€ 20,394 �
Total RRT costs € 74,604 (28,121) 100% € 52,764 (29,889) 100% -€ 21,839 �
Hospital (no RRT) € 10,571 (18,771) 98% € 8,712 (16,672) 96% -€ 1,859 �
Primary care € 249 (352) 100% € 243 (307) 99% -€ 6
Mental health care € 210 (2,122) 7% € 96 (972) 5% -€ 114
Medicationa € 9,442 (6,143) 100% € 9,051 (6,703) 100% -€ 391 �
Medical devices € 743 (1,376) 70% € 625 (1,409) 56% -€ 118 �
Health care abroad € 317 (1,578) 11% € 131 (868) 9% -€ 186
Transportation € 3,001 (3,934) 76% € 1,611 (2,966) 64% -€ 1,390 �
Other € 313 (2,092) 14% € 144 (1,533) 12% -€ 169 �
Total average annual costs € 99,450 (36,036) 100% € 73,376 (38,666) 100% -€ 26,074 �
� = significant at P<0.05 two-sided.
a Medication is all medication distributed by pharmacy outside the hospital. Other types of costs, i.e. dialysis modality and hospitalization may also include medication
costs. In the Netherlands, inpatient medication is part of the DRG and can therefore not be detected as a separate expenditure in claims data.
https://doi.org/10.1371/journal.pone.0220800.t005
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a kidney from a deceased donor. This is likely related to a substantial proportion of living
donor kidney procedures being pre-emptive in the Netherlands. Indeed, 33% of patients
receiving a graft from a living donor did not receive dialysis at all during the year of transplan-
tation. Other factors possibly related to lower expenses for those who receive a living donor
kidney are better survival [23, 24] and less post-operative complications. The latter was con-
firmed in a recent Japanese study also using health claims data. This study showed longer hos-
pitalization and more urinary tract infections, sepsis and pneumonia in recipients of post-
mortal donor kidneys [25]. One further explanation for higher overall costs in patients receiv-
ing a deceased kidney organ is the more frequent occurrence of delayed graft function, associ-
ated with the need for short term post-transplant dialysis [26].
Annual costs decline fast in the first and second year after transplantation, with medication
costs being the highest (30–32% of total cost) component of expenses. These figures include
those for non-successful transplantation (n = 105), hence for patients with graft failure who
had to return to dialysis and patients who died. Combined with the cost advantages of pre-
emptive transplantation as discussed above and the ongoing shortage of deceased donor
organs, this stresses the importance of discussing and exploring the possibility of a living
donor transplantation in pre-dialysis patients. Recently, the Dutch Parliament accepted a
change from opting-in for transplantation after death to an opt-out system, that is expected to
increase the number of deceased donor transplantations in the future. Given the small cost dif-
ferences between pre-emptive transplantation and deceased donor transplantation, relative to
the large cost-differences between any transplantation and dialysis, every transplantation is
expected to contribute to a decrease in costs of RRT.
Following from the source of the data, being insurance claims, we have to face several limi-
tations of our data. First, we have no guarantees that all transplantation related costs of living
donors were registered on the ID of the recipient, with the possible consequence of underesti-
mating the costs of living donors. Second, the donor costs of deceased donors are not at all
part of the claims data, as these are reimbursed outside the basic health insurance. Moreover,
societal costs (e.g., incapability to work) and out-of-pocket costs were not part of this study,
whereas the limited time frame of two post-transplant years prevents us from predicting cost
levels of former transplantation patients in later years. However, as annual costs decline fast
after transplantation and are lowest in those without graft failure, there is no reason to expect
that the cost difference between dialysis and having a functioning transplant kidney will fade
out in later years.
One general limitation to studying costs in terms of expenditure is that expenditure is only
to be seen as an administrative proxy for real costs, implying that it is unknown whether these
costs reflect “true” resource use (both staff and material resources) needed to provide health-
care to these patients. Another important limitation is that we have not related observed differ-
ences in expenditure between modalities to differences in patient characteristics, as we only
had limited information on background characteristics of patients. A previous study on dialy-
sis patients shows that age is associated with expenditures where elderly dialysis patients often
have lower healthcare costs than younger dialysis patients [27]. This knowledge is important
when interpreting the results of our study, where patients in the CHD and CAPD groups were
somewhat older than in other dialysis groups. At least, the number of comorbid diseases were
similar across groups. Other important characteristics, such as frailty, were not known to us.
Summing up, it is likely that differences in expenditures between modalities are related to
(non-)observed differences in patient characteristics and not due to modality characteristics
per se. We feel however that in this specific study it is not the statistical significance of cost dif-
ferences between groups that is of primary interest, but more the actual differences in
expenses, as these are meaningful for health insurers and health policy makers.
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Strengths of our study include the national coverage (>99% of population) of our data, the
inclusion of all RRT modalities, the inclusion of all healthcare use covered by the Health Insur-
ance Act and not only the part that is related to RRT, the good validation of the data with
another national database of RRT patients, and data coverage over a three-year period. We
used a rigorous approach of classifying patients into 1 of 5 dialysis groups and 2 different
transplantation groups, and excluded all patients with erroneous or temporary RRT claims, as
well as patients for whom we had diverging information, e.g. with regard to the weekly number
of dialysis procedures. For the included patients we have high levels of confidence that expen-
diture figures can be attributed correctly to the dialysis modality. Furthermore, as a conse-
quence of our assignment of patients to different treatment groups, we were able to show a
clear picture of cost differences between stable patients using different dialysis modalities.
Because we present cost data also for periods of 4-weeks, we could show that incident and
deceased patients have much higher non-RRT related costs than patients who are stable on
one dialysis modality.
Our data stress the fact that CAPD has a clear cost advantage compared to other home-
based therapy and CHD. Starting as many patients as possible on CAPD could reduce the high
budget impact of RRT to a certain extent. Approximately 1750 patients start dialysis treatment
annually in the Netherlands, of whom 20% start PD (CAPD and APD aggregated) [3]. It is
clear that not all patients are suitable candidates to start with PD, and that a mismatch between
the requirements of the dialysis modality and the patient’s capacity may have detrimental
effects, both on costs and outcomes. However, historically, much higher numbers have started
with peritoneal dialysis in the Netherlands, and even today, center differences in patients start-
ing with PD range from 1 to 46%. This leaves us to conclude that advantages of several million
euros annually could be reached if a start on PD would be considered more often. Obviously,
careful pre-dialysis education followed by shared decision making should ensure that only
patients who are fit for PD are selected to start with this modality. Furthermore, recent
research suggested that the utmost should be done to prevent progression of kidney diseases to
kidney failure, and that prevention holds the promise of spending less health care resources on
RRT [28, 29].
We conclude that annual healthcare expenditures of RRT patients are high, while showing
relevant differences between dialysis modalities at the same time. Frequent haemodialysis
patients have higher RRT related expenditure compared to patients with regular dialysis fre-
quency with similar non-RRT costs. Dialysis patients of the Mix group have the highest annual
expenditure, in particular in the RRT unrelated costs. Annual healthcare costs in the year of
transplantation are high, but decline fast in the years after transplantation. Living donor kid-
ney transplantation incurs lower costs compared to transplantation with a deceased donor kid-
ney. Therefore, our results indicate that the current practice in the Netherlands, where (pre-
emptive) living donor procedures are actively encouraged by nephrologists, is associated with
cost advantages in both the short and longer term. At the same time, budget impact of RRT
could be diminished to a certain extent when more patients would start treatment with home-
based therapies, especially CAPD.
Supporting information
S1 File.
(DOCX)
S2 File.
(DOCX)
Healthcare costs of patients on different renal replacement modalities
PLOS ONE | https://doi.org/10.1371/journal.pone.0220800 August 15, 2019 11 / 14
S3 File.
(DOCX)
S4 File.
(DOCX)
Acknowledgments
The authors thank Vektis for providing access to the health claims data and for assisting with
their comprehensive knowledge regarding analysis of health insurance claims data. We thank
Nefrovisie, the national quality agency for the treatment of kidney diseases and RENINE, the
Dutch Registry of RRT treatment, for providing Registry data for the validation of VEKTIS
data. We thank dr. Cecile Couchoud for sharing her insights on the attribution of patients to
different treatment groups. We are grateful to Henk Bilo, Manon Lette, and Peter Kemper for
the critical reading of a draft version of this article.
Author Contributions
Conceptualization: Sigrid M. Mohnen, Manon J. M. van Oosten, Jeanine Los, Martijn J. H.
Leegte, Marc H. Hemmelder, Susan J. J. Logtenberg, Vianda S. Stel, Leona Hakkaart-van
Roijen, G. Ardine de Wit.
Data curation: Sigrid M. Mohnen, Manon J. M. van Oosten, Jeanine Los, Martijn J. H. Leegte.
Formal analysis: Sigrid M. Mohnen, Manon J. M. van Oosten, Jeanine Los, Martijn J. H.
Leegte.
Funding acquisition: Vianda S. Stel, Leona Hakkaart-van Roijen, G. Ardine de Wit.
Investigation: Sigrid M. Mohnen, Manon J. M. van Oosten, Jeanine Los, Vianda S. Stel, G.
Ardine de Wit.
Methodology: Sigrid M. Mohnen, Manon J. M. van Oosten, Jeanine Los, Martijn J. H. Leegte,
Leona Hakkaart-van Roijen.
Project administration: Sigrid M. Mohnen, Manon J. M. van Oosten, Vianda S. Stel, Leona
Hakkaart-van Roijen, G. Ardine de Wit.
Supervision: Kitty J. Jager, Susan J. J. Logtenberg, Vianda S. Stel, G. Ardine de Wit.
Validation: Marc H. Hemmelder.
Visualization: Jeanine Los.
Writing – original draft: Sigrid M. Mohnen, Manon J. M. van Oosten, Jeanine Los, Kitty J.
Jager, Vianda S. Stel, Leona Hakkaart-van Roijen, G. Ardine de Wit.
Writing – review & editing: Sigrid M. Mohnen, Manon J. M. van Oosten, Jeanine Los, Mar-
tijn J. H. Leegte, Kitty J. Jager, Marc H. Hemmelder, Susan J. J. Logtenberg, Vianda S. Stel,
Leona Hakkaart-van Roijen, G. Ardine de Wit.
References
1. Murray CJ, Barber RM, Foreman KJ, Ozgoren AA, Abd-Allah F, Abera SF, et al. Global, regional, and
national disability-adjusted life years (DALYs) for 306 diseases and injuries and healthy life expectancy
(HALE) for 188 countries, 1990–2013: quantifying the epidemiological transition. Lancet. 2015; 386
(10009):2145–91. https://doi.org/10.1016/S0140-6736(15)61340-X PMID: 26321261
Healthcare costs of patients on different renal replacement modalities
PLOS ONE | https://doi.org/10.1371/journal.pone.0220800 August 15, 2019 12 / 14
2. RIVM. Diseases ordered by costs [Ranglijst ziekten op basis van zorgkosten] Bilthoven, The Nether-
lands: RIVM—National Institut of Public Health and the Environment [updated Retrieved at 15th of
December 2017]. Available from: https://www.volksgezondheidenzorg.info/ranglijst/ranglijst-ziekten-
op-basis-van-zorgkosten
3. Hoekstra T, Hemmelder MH, Van Ittersum FJ. Renine Annual Report 2015. Utrecht: Nefrovisie, 2017.
Retrieved from http://www.nefrovisie.nl/jaarrapportage-2015/ at 15th of December 2017.
4. Pippias M, Jager KJ, Kramer A, Leivestad T, Sa´nchez MB, Caskey FJ, et al. The changing trends and
outcomes in renal replacement therapy: data from the ERA-EDTA Registry. NDT. 2015:gfv327.
5. Vanholder R, Davenport A, Hannedouche T, Kooman J, Kribben A, Lameire N, et al. Reimbursement of
dialysis: a comparison of seven countries. J Am Soc Nephrol. 2012; 23(8):1291–8. https://doi.org/10.
1681/ASN.2011111094 PMID: 22677554
6. de Wit GA, Ramsteijn PG, de Charro FT. Economic evaluation of end stage renal disease treatment.
Health Policy. 1998; 44(3):215–32. Epub 1998/05/07. PMID: 10182294.
7. Mazairac AH, Blankestijn PJ, Grooteman MP, Penne EL, van der Weerd NC, den Hoedt CH, et al. The
cost-utility of haemodiafiltration versus haemodialysis in the Convective Transport Study. Nephrol Dial
Transplant. 2013; 28(7):1865–73. Epub 2013/06/15. https://doi.org/10.1093/ndt/gft045 PMID:
23766337.
8. Oostenbrink JB, Kok ET, Verheul RM. A comparative study of resource use and costs of renal, liver and
heart transplantation. Transpl Int. 2005; 18(4):437–43. https://doi.org/10.1111/j.1432-2277.2004.
00063.x PMID: 15773964.
9. Couillerot-Peyrondet A-L, Sambuc C, Sainsaulieu Y, Couchoud C, Bongiovanni-Delarozière I. A com-
prehensive approach to assess the costs of renal replacement therapy for end-stage renal disease in
France: the importance of age, diabetes status, and clinical events. Eur J Health Econ. 2016:1–11.
10. Icks A, Haastert B, Gandjour A, Chernyak N, Rathmann W, Giani G, et al. Costs of dialysis—a regional
population-based analysis. NDT. 2010; 25(5):1647–52. https://doi.org/10.1093/ndt/gfp672 PMID:
20008830
11. Li B, Cairns JA, Fotheringham J, Tomson CR, Forsythe JL, Watson C, et al. Understanding cost of care
for patients on renal replacement therapy: looking beyond fixed tariffs. NDT. 2015:gfv224.
12. Villa G, Rodrı´guez-Carmona A, Ferna´ndez-Ortiz L, Cuervo J, Rebollo P, Otero A, et al. Cost analysis of
the Spanish renal replacement therapy programme. NDT. 2011; 26(11):3709–14. https://doi.org/10.
1093/ndt/gfr088 PMID: 21427072
13. NZa. ’Scan’ of the health insurance market 2016 [In Dutch: Marktscan Zorgverzekeringsmarkt 2016].
The Dutch Healthcare Authority, 2016. Retrieved from https://www.nza.nl/publicaties/1048188/
Marktscan_Zorgverzekeringsmarkt_2016 at 15th of December 2017.
14. De Boo A. Vektis—information center for health care services [In Dutch: Vektis—Informatiecentrum
voor de zorg’]. TSG. 2011; 89(7):358–9.
15. Hakkaart-van Roijen L, Van der Linden N, Bouwmans CAM, Kanters TA, Tan SS. Costing manual:
Methodology of costing research and reference prices for economic evaluations in healthcare [in Dutch:
Kostenhandleiding: Methodologie van kostenonderzoek en referentieprijzen voor economische evalua-
ties in de gezondheidszorg]. 2015. Institute for Medical Technology Assessment, Erasmus University
Rotterdam, 2015. Retrieved from https://www.zorginstituutnederland.nl/over-ons/publicaties/publicatie/
2016/02/29/richtlijn-voor-het-uitvoeren-van-economische-evaluaties-in-de-gezondheidszorg part 2/2,
at 15th of December 2017.
16. Klarenbach SW, Tonelli M, Chui B, Manns BJ. Economic evaluation of dialysis therapies. Nat Rev
Nephrol. 2014; 10(11):644–52. https://doi.org/10.1038/nrneph.2014.145 PMID: 25157840.
17. Lee H, Manns B, Taub K, Ghali WA, Dean S, Johnson D, et al. Cost analysis of ongoing care of patients
with end-stage renal disease: the impact of dialysis modality and dialysis access. Am J Kidney Dis.
2002; 40(3):611–22. https://doi.org/10.1053/ajkd.2002.34924 PMID: 12200814.
18. McFarlane PA. Reducing Hemodialysis Costs: Conventional and Quotidian Home Hemodialysis in Can-
ada. Semin Dial. 2004; 17(2):118–24. https://doi.org/10.1111/j.0894-0959.2004.17208.x PMID:
15043613
19. Kroeker A, Clark WF, Heidenheim AP, Kuenzig L, Leitch R, Meyette M, et al. An operating cost compari-
son between conventional and home quotidian hemodialysis. Am J Kidney Dis. 2003; 42:49–55. PMID:
12830444
20. Agar JW, Knight RJ, Simmonds RE, Boddington JM, Waldron CM, Somerville CA. Nocturnal haemodia-
lysis: An Australian cost comparison with conventional satellite haemodialysis. Nephrology. 2005; 10
(6):557–70. https://doi.org/10.1111/j.1440-1797.2005.00471.x PMID: 16354238
Healthcare costs of patients on different renal replacement modalities
PLOS ONE | https://doi.org/10.1371/journal.pone.0220800 August 15, 2019 13 / 14
21. Group FHNT, Chertow GM, Levin NW, Beck GJ, Depner TA, Eggers PW, et al. In-center hemodialysis
six times per week versus three times per week. N Engl J Med. 2010; 363(24):2287–300. https://doi.
org/10.1056/NEJMoa1001593 PMID: 21091062; PubMed Central PMCID: PMC3042140.
22. Jaar BG, Plantinga LC, Crews DC, Fink NE, Hebah N, Coresh J, et al. Timing, causes, predictors and
prognosis of switching from peritoneal dialysis to hemodialysis: a prospective study. BMC Nephrol.
2009; 10:3. https://doi.org/10.1186/1471-2369-10-3 PMID: 19200383; PubMed Central PMCID:
PMC2649113.
23. Lamb KE, Lodhi S, Meier-Kriesche HU. Long-term renal allograft survival in the United States: a critical
reappraisal. Am J Transplant. 2011; 11(3):450–62. https://doi.org/10.1111/j.1600-6143.2010.03283.x
PMID: 20973913.
24. ERA-EDTA Registry. ERA-EDTA Registry Annual Report 2015. Amsterdam, the Netherlands: Aca-
demic Medical Center, Department of Medical Informatics, 2017.
25. Kitazawa T, Matsumoto K, Fujita S, Seto K, Hasegawa T. Cost Analysis of Transplantation in Japan,
Performed With the Use of the National Database. Transplant Proc. 2017; 49(1):4–9. https://doi.org/10.
1016/j.transproceed.2016.10.007 PMID: 28104154.
26. Legendre C, Canaud G, Martinez F. Factors influencing long-term outcome after kidney transplantation.
Transpl Int. 2014; 27(1):19–27. Epub 2013/10/22. https://doi.org/10.1111/tri.12217 PMID: 24138291.
27. Van Oosten MJM, Logtenberg SJJ, Leegte MJH, Bilo HJG, Mohnen SM, Hakkaart-van Roijen L, et al.
Age-related difference in healthcare use and costs of patients with chronic kidney disease and matched
controls: analysis of Dutch healthcare claims data Original Article—Clinical Research. NDT. 2019; In
press. https://doi.org/10.1093/ndt/gfz146.
28. Vanholder R, Lameire N, Annemans L, Van Biesen W. Cost of renal replacement: how to help as many
as possible while keeping expenses reasonable? Nephrol Dial Transplant. 2016; 31(8):1251–61. Epub
2015/06/26. https://doi.org/10.1093/ndt/gfv233 PMID: 26109485.
29. Vanholder R, Annemans L, Brown E, Gansevoort R, Gout-Zwart JJ, Lameire N, et al. Reducing the
costs of chronic kidney disease while delivering quality health care: a call to action. Nat Rev Nephrol.
2017; 13(7):393–409. Epub 2017/05/31. https://doi.org/10.1038/nrneph.2017.63 PMID: 28555652.
Healthcare costs of patients on different renal replacement modalities
PLOS ONE | https://doi.org/10.1371/journal.pone.0220800 August 15, 2019 14 / 14
